Success Metrics

Clinical Success Rate

57.6%

Based on 19 completed trials

Completion Rate

58%(19/33)

Active Trials

3(8%)

Results Posted

147%(28 trials)

Terminated

14(37%)

Phase Distribution

Ph phase_2

58%

Ph not_applicable

Ph early_phase_1

Ph phase_3

Ph phase_1

32%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution38 total trials

Early Phase 1First-in-human

1(2.6%)

Phase 1Safety & dosage

12(31.6%)

Phase 2Efficacy & side effects

22(57.9%)

Phase 3Large-scale testing

2(5.3%)

N/ANon-phased studies

1(2.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

54.3%

19 of 35 finished

Non-Completion Rate

45.7%

16 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(19)

Terminated(16)

Detailed Status

Completed19

Terminated14

Recruiting2

Withdrawn2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

57.6%

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (2.6%)

Phase 112 (31.6%)

Phase 222 (57.9%)

Phase 32 (5.3%)

N/A1 (2.6%)

Trials by Status

completed1950%

recruiting25%

active_not_recruiting13%

withdrawn25%

terminated1437%

Recent Activity

3 active trials

Showing 5 of 38

recruitingphase_2

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

NCT07493538

terminatedphase_1

Siplizumab for Sickle Cell Disease Transplant

NCT06078696

active_not_recruitingphase_2

Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

NCT00882895

recruitingphase_2

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

NCT03121001

completedphase_2

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

NCT02441803

View all 38 trials

Clinical Trials (38)

Showing 20 of 38 trialsScroll for more

NCT07493538Phase 2

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Recruiting

NCT06078696Phase 1

Siplizumab for Sickle Cell Disease Transplant

Terminated

NCT00882895Phase 2

Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Active Not Recruiting

NCT03121001Phase 2

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Recruiting

NCT02441803Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Completed

NCT01572662Phase 2

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Completed

NCT01471444Phase 3

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Completed

NCT02660281Phase 1

URMC Related Haplo-identical Donor BMT

Completed

NCT00469014Phase 2

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Completed

NCT00612716Phase 2

Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Completed

NCT00176852Phase 2

Stem Cell Transplant for Hemoglobinopathy

Completed

NCT00368355Phase 2

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

Completed

NCT00651937Phase 2

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Completed

NCT01287104Phase 1

A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

Completed

NCT00539500Phase 2

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

Terminated

NCT01875237Phase 1

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Terminated

NCT02287974Phase 1

Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin

Terminated

NCT00578643Phase 2

Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease

Completed

NCT02489500Phase 3

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

Terminated

NCT00590460Phase 1

Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia

Terminated

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 38